SHANG.FOS.PHARM.GR.H YC 1 (08HH) - Total Liabilities

Latest as of March 2026: €59.30 Billion EUR ≈ $69.32 Billion USD

Based on the latest financial reports, SHANG.FOS.PHARM.GR.H YC 1 (08HH) has total liabilities worth €59.30 Billion EUR (≈ $69.32 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 08HH net assets growth trend to track the company's year-over-year net asset growth rate.

SHANG.FOS.PHARM.GR.H YC 1 - Total Liabilities Trend (2021–2025)

This chart illustrates how SHANG.FOS.PHARM.GR.H YC 1's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does SHANG.FOS.PHARM.GR.H YC 1 generate to measure how efficiently the company converts operating cash flow to free cash.

SHANG.FOS.PHARM.GR.H YC 1 Competitors by Total Liabilities

The table below lists competitors of SHANG.FOS.PHARM.GR.H YC 1 ranked by their total liabilities.

Company	Country	Total Liabilities
Hunan Valin Wire & Cable Co Ltd SHE:001208	China	CN¥3.93 Billion
Northwest Pipe Company NASDAQ:NWPX	USA	$230.41 Million
MapLight Therapeutics, Inc. Common Stock NASDAQ:MPLT	USA	$21.14 Million
Sigma Lithium Resources Corp NASDAQ:SGML	USA	$259.05 Million
Guangzhou Risong Intelligent Technology Holding Co Ltd SHG:688090	China	CN¥940.80 Million
Liberty Latin America Ltd Class C NASDAQ:LILAK	USA	$11.15 Billion
Trinity Capital Inc NASDAQ:TRIN	USA	$1.25 Billion
Shenzhen Urban Transport Planning Center Co. Ltd. SHE:301091	China	CN¥975.06 Million

Liability Composition Analysis (2021–2025)

This chart breaks down SHANG.FOS.PHARM.GR.H YC 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SHANG.FOS.PHARM.GR.H YC 1 stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.93	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.21	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.48	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SHANG.FOS.PHARM.GR.H YC 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)

The table below shows the annual total liabilities of SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€58.21 Billion ≈ $68.06 Billion	+1.19%
2024-12-31	€57.53 Billion ≈ $67.25 Billion	+1.18%
2023-12-31	€56.85 Billion ≈ $66.47 Billion	+7.16%
2022-12-31	€53.05 Billion ≈ $62.03 Billion	+18.09%
2021-12-31	€44.93 Billion ≈ $52.52 Billion	--

About SHANG.FOS.PHARM.GR.H YC 1

F:08HH Germany Drug Manufacturers - Specialty & Generic

Market Cap

$1.17 Billion

€998.18 Million EUR

Market Cap Rank

#8123 Global

#1095 in Germany

Share Price

€1.81

Change (1 day)

-0.55%

52-Week Range

€1.66 - €3.22

All Time High

€4.65